Grow Therapy
Grow Therapy is a mental health platform connecting patients with therapists, handling insurance, billing, and credentialing for providers.
Secondary Market Price
How Grow Therapy Measures Up
To help you manage your Grow Therapy equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Grow Therapy's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Grow Therapy Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Grow Therapy's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Grow Therapy is a mental health platform that connects clients with therapists and provides support for independent providers to establish and manage their practices. The company handles administrative functions for therapists, including insurance credentialing, billing, and client referrals, allowing them to focus on patient care. For clients, the platform offers a search function to find therapists based on criteria such as specialty, insurance plan, identity, and language, with options for both virtual and in-person sessions. Founded in 2020 by Jake Cooper, Alan Ni, and Manoj Kanagaraj, the New York-based company initially focused on helping therapists get in-network with health insurance plans. It has since grown to serve over one million clients through a network of thousands of providers.
Looking forward, Grow Therapy is expanding its operations and research capabilities. The company recently raised $88 million in a Series C funding round in May 2024 and is investing $16 million to establish an innovation hub in New York for AI-based research and development, which is expected to create over 200 new roles. In addition to its New York headquarters, the company has opened a new office in San Francisco. Recent announcements include a partnership with Thatch to add more than 23,000 providers to its marketplace and receiving recognition as a "Best Place to Work" from Built In and one of the "Best Workplaces for Women" by Fortune.
- Sequoia Capital
- Goldman Sachs Alternatives
- PLUS Capital
- Transformation Capital
- SignalFire
- TCV
- Anna Kendrick
- Lily Collins
- Dak Prescott
- Joe Burrow
- Jrue Holiday
- Lauren Holiday
- Co-Founder, Jake Cooper
- Co-Founder, Manoj Kanagaraj
- Co-Founder, Alan Ni
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Grow Therapy worth joining?
Deciding if a startup like Grow Therapy is worth joining involves evaluating the potential value of its equity compensation. A platform like Prospect can help you analyze the offer by projecting your equity's future worth and comparing it to other opportunities.
What should I do with my Grow Therapy stock?
Managing your Grow Therapy stock requires a personalized strategy based on your financial situation and the company's performance. Tools like Prospect provide customized plans for exercising options and selling shares to help maximize your post-tax returns.
Can you sell Grow Therapy stock?
As Grow Therapy is a private company, selling stock is typically limited to specific events like secondary sales, tender offers, or an acquisition. Platforms such as Prospect offer tools to help you navigate these opportunities and decide how much stock to sell for optimal tax efficiency.
How can I find the value of my Grow Therapy stock?
The value of private stock isn't publicly listed, but you can estimate it using the company's latest 409A valuation or recent funding rounds. For more advanced analysis, Prospect uses machine learning models to project your equity's potential future value based on various data points.
What is Grow Therapy's equity worth?
The total worth of your Grow Therapy equity depends on the company's valuation and your specific grant details. By using a platform like Prospect, you can model different scenarios to understand its potential post-tax value, which on average increases by $173,000 for users.
What is Grow Therapy's stock ticker symbol?
Grow Therapy does not have a stock ticker symbol because it is a private company. Ticker symbols are assigned to companies only when they become publicly traded on a stock exchange.
Can I buy or sell Grow Therapy stock?
As a private company, buying Grow Therapy stock is generally restricted to accredited investors or employees with stock options. Selling shares is also limited to company-approved liquidity events, which a platform like Prospect can help you prepare for and optimize.
What is the criteria to buy or invest in Grow Therapy stock?
Investing in a private company like Grow Therapy is typically reserved for venture capital firms, accredited investors, or employees receiving equity compensation. If you are an employee, your eligibility to acquire more stock is defined by the terms of your equity grant.
